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Abstract
Background: The matrix protein of the influenza A virus and the matrix and capsid proteins of
the human immunodeficiency virus (HIV) share striking structural similarities which may have
evolutionary and biological significance. These similarities led us to hypothesize the existence of
cross-reactivity between HLA-A2-restricted FLU-M1:58–66 and HIV-1 p17 GAG:77–85 epitopes.
Methods: The hypothesis that these two epitopes are cross-reactive was tested by determining
the presence and extent of FLU/GAG immune cross-reactivity in lymphocytes from HIV-
seropositive and seronegative HLA-A2+ donors by cytotoxicity assays and tetramer analyses.
Moreover, the molecular basis for FLU/GAG cross-reactivity in HIV-seropositive and seronegative
donors was studied by comparing lymphocyte-derived cDNA sequences corresponding to the
TCR-β variable regions, in order to determine whether stimulation of lymphocytes with either
peptide results in the expansion of identical T-cell clonotypes.
Results: Here, we report evidence of cross-reactivity between FLU-M1:58–66 and HIV-1 p17
GAG:77–85 epitopes following in vitro stimulation of PBMC derived from either HIV-seropositive
or seronegative HLA-A2+ donors as determined by cytotoxicity assays, tetramer analyses, and
molecular clonotyping.
Conclusion: These results suggest that immunity to the matrix protein of the influenza virus may
drive a specific immune response to an HLA-A2-restricted HIV gag epitope in HIV-infected and
uninfected donors vaccinated against influenza.
Background
The matrix protein of the influenza A virus and the matrix
and capsid proteins of human immunodeficiency virus 1
(HIV-1) share striking structural similarities [1]. When the
influenza and HIV matrix proteins were compared by
aligning selected stretches of their amino acid chains
(from areas that produced similar three-dimensional pro-
tein structure, rather than shared amino acid sequence
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homology), the HLA-A2-restricted FLU-M1:58–66 pep-
tide (GILGFVFTL) [2] was almost perfectly aligned with
the sequence SLYNTIAVL at the level of the Helix 4
domain. This sequence is a variant of the HIV-1 clade B
p17 GAG:77–85 epitope consensus sequence (SLYNT-
VATL) [3], widely utilized as an HLA-A2-restricted HIV
matrix epitope. This coincidence led us to investigate pos-
sible cross-reactivity between FLU-M1:58–66 and
GAG:77–85 epitopes in cytotoxicity experiments follow-
ing in vitro stimulation of PBMC derived from either HIV-
seropositive or seronegative HLA-A2+ donors.
We report in the present study that PBMC from different
HLA-A2+, HIV-infected donors, stimulated in vitro with
FLU-M1:58–66 or GAG:77–85 peptide in the presence of
interleukin-2 (IL-2), were capable of HLA-restricted kill-
ing of target cells loaded with either FLU-M1:58–66 or
GAG:77–85 peptide. These cytotoxic activities correlated
with binding of stimulated CD8+ T lymphocytes with
FLU-M1:58–66 and GAG:77–85 HLA-A2 tetramers [4].
These results are consistent with the concept that immu-
nity to structural components of the influenza virus may
result in a cross-reactive response to structural compo-
nents of HIV in infected patients.
In vitro stimulation of PBMC from HLA-A2+, seronegative
donors with FLU-M1:58–66 or GAG:77–85 peptide also
generated measurable cross-reactive responses to each
epitope as measured by cytotoxicity studies. Analysis of
the  β-chain gene of the T-cell receptor (TCR) in lym-
phocytes from one of the seronegative donors strongly
suggests that cross-recognition of FLU-M1:58–66 and
GAG:77–85 epitopes results from in vitro expansion of
influenza-specific memory T cells.
Methods
Human Subjects and derivation of PBMC
Blood donors were enrolled according to a protocol
approved by the Institutional Review Board (HR# 7748)
at the Medical University of South Carolina and were
tested for both HIV antigen and antibody immediately
before leukapheresis (the designation "infected" donors
refers only to their HIV status; the designation "unin-
fected" donors refers only to their HIV seronegativity). To
obtain PBMC, leukapheresis samples from donor individ-
uals were centrifuged through a ficoll gradient (Lym-
phocyte Separation Medium, Organon Teknika, Durham,
NC, USA) according to manufacturer's instructions. HlV-
seropositive donors were receiving highly-active anti-ret-
roviral treatment and had a blood CD4 count of at least
300/mm3.
Peptides
FLU-M1:58–66 (GILGFVFTL) [2], HIV-1 p17 GAG:77–85
(SLYNTVATL) [3], and GP100:209–217 (ITDQVPFSV) [5]
peptides were synthesized by Cell Essentials, Inc. (Boston,
MA, USA) and purified to >95%. Stock solutions of pep-
tides were prepared in dimethyl sulfoxide (Mallinckrodt
Baker, Phillipsburg, NJ, USA).
In vitro stimulation of PBMC
PBMC derived from leukapheresis of donors were stimu-
lated in vitro for two-weeks in Iscove's media (Life Tech-
nologies) supplemented with 10% human AB serum
(Sigma, St. Louis, MO, USA), 300 IU/mL IL-2 (Proleukin,
Chiron Corporation, Emeryville, CA, USA), plus antigenic
peptides (1 µg/mL FLU-M1:58–66 peptide, 5 µg/mL
GAG:77–85 or GP100:209–217 peptides).
Cytotoxicity assays
Effector cells were derived from stimulation of donor
PBMC as described above. T2 target cells [6] were loaded
overnight at 26°C with 100 µCi Cr51 (as sodium chro-
mate, Amersham Pharmacia, Piscataway, NJ, USA) plus 5
µg/mL of the appropriate peptide (cells not loaded with
peptide were used as control targets). Effector and target
cells were incubated together for four hours at 37°C at
indicated ratios. Maximum and minimum Cr51-release
were calculated by incubating aliquots of target cells
(loaded with peptides or control) in sodium dodecyl sul-
fate or medium, respectively. Cr51-release was measured
by gamma counter. Percent lysis reflects the average of
triplicate samples.
Tetramer analyses
PE-labeled FLU-M1:58–66/HLA-A2.1 and GAG:77–85/
HLA-A2.1 tetramers [4] were purchased from Immunom-
ics (Beckman Coulter, Fullerton, CA, USA). PBMC stimu-
lated in vitro as described above were subjected to
immunofluorescence cell surface staining with tetramers
plus FITC-labeled anti-CD8 mAb (Beckman Coulter). To
exclude dead cells, the dye 7-amino-actinomycin D (7-
AAD; BD PharMingen, San Jose, CA, USA) was added
before fixation, according to manufacturer's instructions.
Stained cells were fixed with 2% formaldehyde and sub-
jected to flow cytometry analysis using a Becton-Dickin-
son cell analyzer (Franklin Lakes, NJ, USA).
TCR clonotype mapping
PBMC from HIV-seronegative donor 1 were subjected to
in vitro stimulation with FLU-M1:58–66 or GAG:77–85
peptides as described above. Cell separation was then per-
formed by a modification of the procedure as previously
described [7]. Briefly, 100 µL of streptavidin microbeads
(Miltenyi Biotec, Auburn, CA, USA) were conjugated to 20
pmol biotinylated HLA-A2/FLU-M1:58–66 monomers
(synthesized according to standard protocols for tetramer
construction found on the NIAID Tetramer Facility web-
site) by incubating the mixture for 15 min at room tem-
perature and removing the unbound monomers byJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/3
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spinning the beads and washing twice. HLA-A2/FLU:58–
66-conjugated beads were then used to label cells stimu-
lated with either FLU-M1:58–66 or GAG:77–85 peptide,
followed by separation of the bead-bound cells by passing
through a MACS MS separation column (Miltenyi Biotec),
all according to the manufacturer's instructions. Total
RNA was purified from each cell type using a Perfect RNA
kit (Eppendorf Scientific, Westbury, NY, USA) and cDNA
synthesized by the ProStar First-Strand RT-PCR kit (Strat-
agene, La Jolla, CA, USA) using an oligo(dT) primer.
PCR amplification of TCR BV regions for each cell type
was performed using primer sequences (all BV primers
plus the GC-clamped BCseq2 primer) and protocols as
previously reported [8], taking appropriate precautions to
prevent cross-contamination of samples. All primers were
synthesized by the Great American Gene Company (Ram-
ona, CA, USA) and Taq 2000 DNA polymerase (Strata-
gene) was used for PCR. PCR products were analyzed by
electrophoresis through a 1.8% agarose gel in 1X TBE and
stained with ethidium bromide. Some samples were also
analyzed by denaturing gradient gel electrophoresis as
described [7]. Briefly, samples were run in a 6% polyacry-
lamide gel containing a gradient of urea and formamide
from 20–80% (160 V, 4.5 hr, 58°C) and stained with
ethidium bromide. For DNA sequencing, bands on the
DGGE polyacrylamide gel were excised under UV light,
and DNA extracted from the gel slices was re-amplified by
PCR using appropriate BV and BC primers. The resultant
PCR products were then purified by separation on an aga-
rose gel, followed by excision of each band and DNA
extraction. The purified DNAs were then sent to the MUSC
Biotechnology Core for sequencing in both forward (BV
primer) and reverse (BC primer) directions.
Results
Cross-recognition of influenza- and HIV-derived epitopes 
in HIV-seropositive donors
Three HLA-A2+, HIV-seropositive donors (under highly-
active anti-retroviral treatment and with a blood CD4
count of at least 300/mm3) underwent leukapheresis, and
their PBMC were purified by centrifugation through a
ficoll gradient. Following a two-week in vitro stimulation
of PBMC with either influenza A-derived FLU-M1:58–66
or HIV-1-derived p17 GAG:77–85 peptide in the presence
of IL-2, effector cells were tested in 51Cr-release assays
against the following targets: 1) unloaded HLA-A2+ T2
cells (no peptide); 2) T2 cells loaded with FLU-M1:58–66
peptide; 3) T2 cells loaded with GAG:77–85 peptide; and
4) T2 cells loaded with the unrelated, melanoma-associ-
ated GP100:209–217 [5] peptide. The results of these
cytotoxicity experiments (Fig. 1) show that for HIV+
Donor 1 and to a lesser extent HIV+ Donor 2, effector cells
stimulated with the FLU-M1:58–66 peptide lysed not only
target cells presenting FLU-M1:58–66 peptide, but also
target cells presenting the GAG:77–85 peptide. Con-
versely, effector cells from HIV+ Donor 3 (and to a lesser
extent HIV+ Donor 2) stimulated with the GAG:77–85
peptide were able to lyse T2 cells presenting either the
GAG:77–85 or FLU-M1:58–66 peptides. It is worth noting
that lymphocytes from Donor 3 demonstrated very strong
cytolytic activity after stimulation with antigenic peptides,
hence the lower effector:target ratios shown in Fig. 1. No
cytotoxicity above background was demonstrated against
target cells presenting the HLA-A2-restricted, melanoma-
associated GP100:209–217 peptide or when effector cells
were stimulated with IL-2 in the absence of peptide
(PBMC alone), suggesting that the observed cross-reactiv-
ity is dependent on the in vitro expansion of memory T
cells in the presence of their cognate epitopes.
In parallel, the phenotypes of peptide-stimulated effector
cell populations from these patients were also analyzed
using HLA tetrameric complexes (Fig. 2). The results of
these flow cytometry studies indicate that, after stimula-
tion with FLU-M1:58–66 peptide in the presence of IL-2,
CD8+ T lymphocytes from HIV+ Donor 1 recognized both
FLU-M1:58–66 and GAG:77–85 HLA-A2 tetramers. In
addition, GAG:77–85-stimulated CD8+  T lymphocytes
from HIV+ Donor 3 recognized both GAG:77–85 and
FLU-M1:58–66 tetramers. GAG:77–85 CD8+  T lym-
phocytes from HIV+ Donor 2 also recognized FLU-M1:58–
66 tetramers, but to a much lesser extent than HIV+ Donor
3 (data not shown). It is not surprising that, despite the
fact that the GAG:77–85 peptide has been determined to
be the immunodominant p17-GAG antigenic epitope in
HLA-A2+  individuals, the percentage of GAG-specific
CD8+ cells in the donor PBMC population is too low to be
seen with either tetramer staining or cytotoxicity assays
unless reactive clones have first been specifically-
expanded by in vitro peptide stimulation (this is also true
of the FLU-M1:58–66 epitope in most donor samples).
Lymphocytes from three additional HLA-A2+, HIV-serop-
ositive donors were also tested by cytotoxicity assays and
tetramer analyses. Effector cells from these three patients
failed to respond to either FLU-M1:58–66 or GAG:77–85
peptide stimulation; therefore, no cross-reactivity was
observed, indicating that their T-cell-mediated recall
response was severely compromised. This is not surpris-
ing, considering that two of these patients had previously
exhibited a nadir in CD4+ cell counts of 66 and 80 cells/
mm3, and the third donor was experiencing a variety of
immunocompromising ailments. These observations are
consistent with our previously published report showing
that stimulation of HIV-1 envelope-specific cytotoxic T
lymphocytes (CTL) was observed in three out of six HIV-
infected donors tested for their recall responses against
viral antigens [9]. Therefore, in vitro stimulation seemsJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/3
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Cytotoxic responses by lymphocytes from HIV-seropositive donors Figure 1
Cytotoxic responses by lymphocytes from HIV-seropositive donors. Results are shown of representative cytotoxicity 
assays (Cr51-release) using stimulated lymphocytes derived from three HLA-A2+, HIV-seropositive donors. Effector cells were 
mixed with T2 target cells presenting HLA-A2-restricted influenza A-derived FLU-M1:58–66 (■ ) or HIV-1-derived p17 
GAG:77–85 (▲ ) peptide. T2 cells loaded with GP100:209–217 (● , Donors 1 and 2 only) or no peptide (◆ ) were used as con-
trols as shown. Effector cells were tested after in vitro stimulation of PBMC with IL-2 and: no peptide (PBMC alone); FLU-
M1:58–66; or GAG:77–85 peptide. Data points refer to percent lysis at indicated effector:target ratios.
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unable to rescue a measurable CTL response from subjects
who may have lost a considerable portion of their mem-
ory T-cell repertoire.
Control experiments to demonstrate HLA-restriction per-
formed with PBMC derived from an HLA-A2-negative,
HIV-infected donor showed that FLU-M1:58–66 or
GAG:77–85 HLA-A2-restricted peptides were unable to
stimulate either specific lysis of FLU-M1:58–66 or
GAG:77–85 loaded target cells, or recognition of FLU-
M1:58–66 and GAG:77–85 HLA-A2 tetramers by this
patient's lymphocytes (data not shown).
Cross-recognition of influenza- and HIV-derived epitopes 
in seronegative donors
The results of the cytotoxicity and tetramer studies on the
PBMC from the HLA-A2+, HlV-seropositive donors led us
to investigate the possibility that HLA-A2-restricted cross-
reactivity between FLU-M1:58–66 and GAG:77–85
epitopes might also be observed in lymphocytes from
uninfected individuals. Therefore, we obtained PBMC
from three HLA-A2+, seronegative donors. Following
stimulation of PBMC with FLU-M1:58–66 or GAG:77–85
peptide in the presence of IL-2, effector cells were tested in
cytotoxicity experiments as described for the HIV-seropos-
Tetramer analyses of lymphocytes from HIV-seropositive donors Figure 2
Tetramer analyses of lymphocytes from HIV-seropositive donors. After in vitro stimulation with IL-2 plus either FLU-
M1:58–66 or HIV p17 GAG:77–85 peptide (or no peptide as background), lymphocytes from HLA-A2+, HIV-seropositive 
Donors 1 and 3 were stained with FITC-labeled anti-CD8 mAb and either HLA-A2/FLU-M1:58–66 tetramer or HLA-A2/
GAG:77–85 tetramer (both PE-labeled), as indicated, and viable cells were analyzed by flow cytometry (nonviable cells positive 
for staining with the dye 7-AAD were excluded). Percentages of CD8+ cells that stain with tetramer appear in the upper-right 
quadrant of the histograms.
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Cytotoxic responses by lymphocytes from HIV-seronegative donors Figure 3
Cytotoxic responses by lymphocytes from HIV-seronegative donors. Results are shown of representative cytotoxic-
ity assays (Cr51-release) using stimulated lymphocytes derived from three HLA-A2+, HIV-seronegative donors. Effector cells 
were mixed with T2 target cells presenting HLA-A2-restricted influenza A-derived FLU-M1:58–66 (■ ) or HIV-1-derived p17 
GAG:77–85 (▲ ) peptide. T2 cells loaded with GP100:209–217 (● , Donors 1 and 2 only) or no peptide (◆ ) were used as con-
trols as shown. Effector cells were tested after in vitro stimulation of PBMC with IL-2 and: no peptide (PBMC alone); FLU-
M1:58–66; or GAG:77–85 peptide. Data points refer to percent lysis at indicated effector:target ratios.
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itive donor cells above. For all three donors, effector cells
stimulated with FLU-M1:58–66 peptide were able to spe-
cifically lyse target cells loaded with either FLU-M1:58–66
or GAG:77–85, indicating that it is possible to induce a
primary in vitro response to an HIV-derived epitope in
lymphocytes from seronegative subjects because of cross-
reactivity between FLU-M1:58–66 and GAG:77–85
epitopes (Fig. 3). Stimulation of PBMC from Donors 1
and 2 with GAG:77–85 peptide resulted in some lysis of
FLU-M1:58–66-loaded target cells, but no significant lysis
of GAG:77–85-loaded target cells.
These cytotoxicity results suggest that stimulation of
PBMC with FLU-M1:58–66 peptide induces the expan-
sion of cognate memory T cells and the expansion of CTL
that lyse not only target cells presenting FLU-M1:58–66,
but also target cells presenting GAG:77–85. On the other
hand, the absence in these seronegative subjects of
GAG:77–85-specific memory T cells explains why PBMC
stimulation with this peptide does not generate any meas-
urable GAG:77–85-specific CTL activity. Interestingly,
however, in seronegative donors 1 and 2, stimulation
with GAG:77–85 results in the induction of a small but
measurable CTL activity against FLU-M1:58–66-loaded
target cells, consistent with the possibility that the
GAG:77–85 peptide was able to stimulate the expansion
of some FLU-M1:58–66 memory T cells because of cross-
reactivity. Despite these repeatable results in multiple
cytotoxicity assays, we could not definitively demonstrate
the existence of GAG-specific, CD8+ lymphocytes in unin-
fected individuals by tetramer analyses (data not shown).
PBMC from two additional HLA-A2+, HlV-seronegative
donors were tested that demonstrated a very weak or
absent response to FLU-M1:58–66 or any other epitope
examined in both cytotoxicity assays and tetramer analy-
ses, suggesting that cross-reactivity can only be observed
in subjects exhibiting a strong recall response to influenza.
Clonotype analysis of cross-reactive T cells
Because of the cross-reactivity between FLU-M1:58–66
and GAG:77–85 epitopes, we investigated whether in
vitro stimulation of PBMC from seronegative Donor 1
with FLU-M1:58–66 and GAG:77–85 epitopes results in
expansion of any identical T-cell clonotypes. Therefore,
we performed TCR clonotype mapping by RT-PCR and
denaturing gradient gel electrophoresis (DGGE) [7,8].
This procedure can be used to quickly detect clonally
expanded T cells in a mixed T-cell population based on
the differences in rearrangement of TCR genes from clone
to clone. In most studies reported to date, this type of
analysis has demonstrated that antigen-specific T cells are
usually oligoclonal subpopulations of occasionally doz-
ens of individual clones [7,8].
For this procedure, PBMC from this seronegative donor
were subjected to in vitro stimulation with either FLU-
M1:58–66 or GAG:77–85 peptides in the presence of IL-2,
and the resulting lymphocytes purified by binding the
cells to FLU-M1:58–66/HLA-A2 monomers conjugated to
magnetic microbeads [7]. By attaching FLU-M1:58–66/
HLA-A2 molecules to the microbeads, FLU-M1:58–66-
specific T cell populations can be identified by separating
bead-bound cells in a magnetic field. We observed that
over ten-fold more FLU-M1:58–66-stimulated cells than
GAG:77–85-stimulated cells bound to the magnetic
microbeads conjugated with FLU-M1:58–66/HLA-A2.
To determine if these FLU-M1:58–66-specific T cells iso-
lated from both FLU-M1:58–66-or GAG:77–85-stimu-
lated cell populations shared any of the same
rearrangements of the TCR-β chain gene, RNA was puri-
fied from each of these two cell populations and used as
templates for making cDNA by reverse transcription. RT-
PCR was then used to amplify possible transcripts for each
of the 24 TCR β-variable gene (BV) regions or families
(each region is amplified by the use of a common BC
primer that binds in the TCR-β constant region and spe-
cific BV primer that binds in the TCR BV region; each
primer pair will produce PCR products in a limited size
range of about 150 to 300 bp in length; some BV families
require two different BV primers to encompass all mem-
bers of that BV family). To simplify analysis of the large
number of samples, we first analyzed PCR products by
electrophoresis in a 1.8% agarose gel. In this gel, all clones
within a BV family were resolved based on their size. For
the PCR products from FLU-M1:58–66-stimulated cells,
clonotypes from at least 15 BV families were represented;
for the PCR products from GAG:77–85-stimulated cells,
clonotypes from at least 14 BV families were represented
(data not shown). The results of this gel clearly demon-
strated that FLU-M1:58–66-specific T cells from this
donor are oligoclonal and belong to several different TCR
BV families.
For 12 BV families that appeared, by agarose gel electro-
phoresis, to share clones between FLU-M1:58–66- and
GAG:77–85-stimulated cells, PCR products were then
resolved by DGGE to determine if any clones were indeed
identical. This procedure can identify the presence of indi-
vidual clones within a BV family by gel electrophoresis
through a gradient of denaturants, during which different
DNA molecules will partially melt at different locations
based on their nucleotide composition, and their migra-
tion will be retarded. As a result of this gel-shift phenom-
enon, distinct bands will be seen on the gel even if DNA
species of identical length differ in only a single base pair
of their sequence [10].Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/3
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This analysis clearly showed that most bands of identical
size on the agarose gel actually represented species of dif-
ferent nucleotide composition, as multiple bands
resolved in most lanes of the DGGE. Moreover, some
identical clonotypes between FLU-M1:58–66- and
GAG:77–85-stimulated cells were seen in 5 of the 12 fam-
ilies BV families that shared clones (Fig. 4), consistent
with the concept that stimulation of PBMC from this
seronegative donor by either FLU-M1:58–66 or GAG:77–
85 peptide results in expansion of some of the same FLU-
M1:58–66-specific T-cell clonotypes, which the cross-rec-
ognition observed in cytotoxicity experiments and
tetramer analyses. (For the sake of clarity, figure 4 was
constructed to highlight the evidence of cross-reactivity,
but as expected with two different peptides, many clones
expanded by in vitro stimulation were, in fact, species of
different nucleotide composition. Cross-reactive peptides
would only be expected to induce some of the same FLU-
M1:58–66-specific clonotypes).
To further verify that in vitro stimulation of PBMC (from
HIV-seronegative donor 1) with either FLU-M1:58–66 or
GAG:77–85 epitopes results in the expansion of some
identical T-cell clonotypes, two identically migrating, eas-
ily accessible bands on the DGGE polyacrylamide gel were
excised, purified, and sequenced. The results of DNA
sequencing confirmed that these distinct bands exhibiting
identical migration in DGGE are indeed identical in
sequence (Fig. 5).
Future experiments will hopefully determine the propor-
tion of T-cell clones that are cross-reactive by simultane-
ously staining lymphocyte populations with both FLU
and GAG tetramers conjugated to different fluoro-
chromes. It may also be possible to isolate cross-reactive
clonotypes using flow cytometry.
Discussion
In their seminal work on CTL response to cross-reactive
viral epitopes, Selin, Welsh, and their collaborators
emphasized that T-cell-mediated cross-reactivity is a far
more widespread phenomenon than anticipated and may
provide an explanation for the natural resistance to subse-
quent viral infections. The expansion of cross-reactive
memory T lymphocytes following low-affinity cross-reac-
tive interactions may be facilitated by the expression in
these cells of ancillary molecules that lower the threshold
of activation and enhance the killing of cognate target
cells [11]. The pre-existing cross-reactive T-cell immunity
can enhance clearance of a second, unrelated viral infec-
tion [12,13], although the sequence of viral infections is
important and cross-protection is not necessarily recipro-
cal [14]. There may be a positive selection in favor of
cross-reactive memory T cells compared to non-cross-reac-
tive cells, which would be lost over time; such selection
would contribute to a more efficient use and better home-
ostasis of the immune system [15]. Interestingly, little or
no sequence homology between epitopes may be required
for cross-recognition [16,17], consistent with the molecu-
lar mimicry model of cross-reactivity [18,19]. This may
explain how the very large, but not unlimited repertoire of
T-cell receptor specificities can accommodate a virtually
endless variety of possible antigenic epitopes. The exist-
ence of a possible immunodominance hierarchy among
cross-reactive epitopes [20] may also explain the non-
symmetrical, non-reciprocal character of cross-reactivity,
as we have also observed between FLU-M1:58–66 and
GAG:77–85; although both epitopes are immunodomi-
nant, FLU-M1:58–66 appears to be the stronger of the
two.
Clonotype analysis of FLU- and GAG-stimulated lymphocytes Figure 4
Clonotype analysis of FLU- and GAG-stimulated lym-
phocytes. Some identical FLU-specific clonotypes between 
FLU- and GAG-stimulated T cells were observed in 5 BV 
families analyzed by denaturing gradient gel electrophoresis 
(DGGE). PBMC from a HIV-seronegative Donor 1 were 
stimulated in vitro with FLU-M1:58–66 or GAG:77–85 pep-
tides, and the resulting FLU-M1:58–66-specific cells purified 
by binding cells with the cognate TCR to HLA-A2/FLU-
M1:58–66 peptide monomers conjugated to magnetic 
microbeads. RT-PCR was performed on RNA derived from 
each cell type (FLU-M1:58–66- or GAG:77–85-stimulated) 
using primers specific for all 24 TCR-β (BV) families. Each 
band resolved on a DGGE gel represents different clono-
types separated according to their nucleotide composition. 
The results of five different primers are shown here (BV13a 
is one of the two variable primers needed to amplify all pos-
sible members of the BV13 family).
BV4
 FLU  GAG
BV13a
FLU  GAG
BV14
FLU  GAG
BV17
 FLU  GAG
BV19
 FLU  GAGJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/3
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In other recent studies, Schlom and coworkers have devel-
oped a carcinoembryonic antigen (CEA) transgenic
mouse model in which the human CEA transgene is
expressed in fetal tissue and normal colonic mucosa at
levels virtually identical to that found in humans [21].
They have demonstrated that these mice are tolerant to
CEA as an immunogen when CEA protein in adjuvant is
used as a vaccine. However, when the CEA gene is inserted
into a vaccinia virus vector (rV-CEA), or into a recom-
binant avipox vector (avi-CEA/rF-CEA), and used as an
immunogen, these CEA transgenic mice now mount a T-
cell response directed against CEA [22]. Additional studies
have shown that the T-cell response in CEA transgenic
mice vaccinated with rV-CEA is much higher and
sustained than the T-cell response in transgenic mice vac-
cinated with CEA protein alone [James Gulley, personal
communication]. It is tempting to speculate that the role
of the viral component of the rV-CEA vaccine may, at least
in part, be the result of cross-reactivity, as the viral
epitopes are able to mobilize large numbers of memory
cells, some of which also recognize CEA-derived epitopes.
The cross-reactivity between FLU-M1:58–66 and
GAG:77–85 is of particular interest since it involves two of
the most intensively studied immunodominant epitopes.
Cross-reactivity between FLU-M1:58–66 and a rotavirus
epitope was previously reported [23] and recently, CTL-
mediated cross-reactivity between hepatitis C virus (HCV)
and influenza A virus has also been reported. This cross-
reactivity appears to be the consequence of extensive
sequence homology between the epitopes of the two
viruses and is observed in 55–60% of tested individuals,
either HCV-infected or uninfected [24].
Although a T-cell-mediated immune response against
GAG:77–85 is readily measurable in most HLA-A2+,
chronic HIV carriers, this epitope does not appear to be
recognized following acute infection or vaccination [[25–
27]; Kent Weinhold, personal communication]. There-
fore, it seems interesting to observe a specific cytotoxic
response against GAG:77–85 in three out of five seroneg-
ative donors following in vitro stimulation of their PBMC.
The results of the cytotoxicity studies and tetramer analy-
ses support the notion that the process of in vitro stimula-
tion in the presence of FLU-M1:58–66 peptide and IL-2
activates FLU-M1:58–66-specific memory T cells, which
are able to cross-recognize and lyse target cells presenting
GAG:77–85. Therefore, the primary in vitro response
against the GAG:77–85 epitope in seronegative subjects
would be the result of FLU-M1:58–66/GAG:77–85 cross-
reactivity. The small number of donors analyzed in this
study prevents us from assessing the prevalence of the
FLU-M1:58–66/GAG:77–85 cross-reactivity among HLA-
A2+ individuals, and future studies would be necessary to
fully characterize the relationship between the magnitude
of the recall response to FLU-M1:58–66 and the extent of
cross-reactivity involving GAG:77–85, including any pos-
sible correlations to flu vaccination history.
Conclusions
In a recently published study on clonality of HIV-specific
T-cell response, it has been proposed that epitopes
DNA sequencing of identical TCR-β clonotypes Figure 5
DNA sequencing of identical TCR-β clonotypes. 100% sequence identity of the TCR-β-variable gene region of FLU- or 
GAG-stimulated lymphocytes was obtained using a BV17 primer. This sequence includes the CDR3 hypervariable D/J region 
between the 'CASS' coding sequence and the BC region (both in gray), which greatly influences the HLA/peptide binding specif-
icity of the TCR molecule.
FLU    1   agaggaatcctttcctctactgtgacatcggcccaaaagaacccgacagctttctatctc 60 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GAG    1   agaggaatcctttcctctactgtgacatcggcccaaaagaacccgacagctttctatctc 60 
CASS
FLU    61  tgtgccagtagtgtacggacctgctacgagcagtacttcgggccgggcaccaggctcacg 120 
GAG    61  tgtgccagtagtgtacggacctgctacgagcagtacttcgggccgggcaccaggctcacg 120 
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BC primer
FLU    121 gtcacagaggacctgaaaaacgtgttcccacccgaggtcgctgt 164 
           |||||||||||||||||||||||||||||||||||||||||||| 
GAG    121 gtcacagaggacctgaaaaacgtgttcccacccgaggtcgctgt 164 Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/3
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capable of engaging a multiplicity of T-cell clonotypes
may help control viral escape [28]. Consistent with these
observations, it is tempting to speculate that immunodo-
minant epitopes are capable of engaging a greater variety
of T-cell clonotypes, and they would exhibit a greater like-
lihood of cross-reactivity with different epitopes that
engage some of the same clonotypes. Therefore, our
experimental observations on the cross-recognition
between the influenza A-derived, HLA-A2-restricted FLU-
M1:58–66 epitope and the HIV-1-derived, HLA-A2-
restricted HIV p17 GAG:77–85 epitope may have practical
applications not only for immunotherapy of HIV-infected
patients, but also for the prevention of HIV infection in
healthy subjects, raising the possibility of inducing a pro-
tective immune response against HIV by identifying
appropriate combinations and formulations of influenza-
and HIV-derived antigens to be used as vaccines.
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